T cell receptor recognition of prostate-specific antigen peptide–major histocompatibility complex

T cell receptor recognition of the prostate-specific antigen peptide–MHC complex refers to the molecular interaction by which a T cell receptor (TCR) on cytotoxic T lymphocytes binds a short peptide fragment derived from prostate-specific antigen (PSA) that is presented on the cell surface by a class I MHC molecule. This recognition is central to the adaptive immune response against prostate tumor cells, as it enables T cells to specifically target and lyse prostate cancer cells presenting the PSA peptide in the context of the correct MHC allele. Such peptide–MHC interactions underlie efforts to develop peptide vaccines, adoptive T cell therapies, and TCR-mimic antibodies for prostate cancer immunotherapy. However, the phrase itself describes a functional event, not a discrete molecular entity; proper structure-based and sequence-based definitions apply to the individual constituents: the TCR (a heterodimeric receptor), the PSA peptide (antigenic fragment), and the MHC molecule (typically HLA-A2 in prostate cancer studies).

Other names

TCR–PSA peptide–MHC interactionTCR recognition of PSA pMHCTCR recognition of prostate-specific antigen peptide–MHCTCR–peptide–MHC interaction involving PSA

Recognition of PSA-derived peptide by TCR triggers T cell activation by signaling through TCR complex upon binding the specific PSA-peptide–MHC ligand. Downstream consequences: T cell proliferation, cytokine release, cell-mediated cytotoxicity